Atlas Trials

Gemcitabine/Nab-Paclitaxel With HIGRT in Resectable Pancreatic Cancer

Clinical trial NCT02318095 · COMPLETED

Trial details

NCT number
NCT02318095
Sponsor
Duke University
Status
COMPLETED
Phase
Not Applicable
Study type
INTERVENTIONAL
Resectable Pancreatic Cancers
Start date
2015-02-17
Primary completion
2018-11-07
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.